Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2 1

Status

Unknown 3

Sponsor Class

INDUSTRY 3OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Gynecologic 1

Conditions

Neoplasms 2Recurrence 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Genes, p53 × Clear all
NCT02435186 2015-05-06

p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Shenzhen SiBiono GeneTech Co.,Ltd

Phase 2 Unknown
100 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT00894153 2012-04-09

p53 Gene Therapy for Head and Neck Malignant Tumors in Advanced Stage

Shenzhen SiBiono GeneTech Co.,Ltd

Phase 4 Unknown
1,200 enrolled
Tumor-Agnostic

Neoplasms

NCT00902083 2012-04-09

rAd-p53

Shenzhen SiBiono GeneTech Co.,Ltd

Phase 4 Unknown
600 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡